Comparison of treatment response in second-episode versus first-episode schizophrenia

Journal of Clinical Psychopharmacology

Volumn 33, Issue 1, 2013, Pages 80-83

  Emsley, Robin ^a   Oosthuizen, Petrus ^a   Koen, Liezl ^a   Niehaus, Dana ^a   Martinez, Lupe ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

nonresponse; relapse; schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; LORAZEPAM; MOOD STABILIZER; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RELAPSE; REMISSION; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS; KAPLAN-MEIER ESTIMATE; MALE; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; REMISSION INDUCTION; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THERAPEUTICS; TIME FACTORS; YOUNG ADULT;

EID: 84873077628     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31827bfcc1     Document Type: Article

References (24)

1. Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(suppl 14):27-30.
2. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.
3. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:325-351.
4. Lieberman JA, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50:369-376.
5. Lieberman JA, Alvir JM, Koreen A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14:13S-21S.
6. Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975-983.
7. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549.
8. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50:898-911.
9. Levine SZ, Lurie I, Kohn R, et al. Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophrenia Res. 2011;126:184-191.
10. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991;48:739-745.
11. Curson DA, Barnes TR, Bamber RW, et al. Long-term depot maintenance of chronic schizophrenic out-patients: the seven-year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome. Br J Psychiatry. 1985;146:474-480.
12. Wiersma D, Nienhuis FJ, Slooff CJ, et al. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull. 1998;24:75-85.
13. Glovinsky D, Kirch DG, Wyatt RJ. Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry. 1992;31:968-970.
14. McGlashan TH. Is active psychosis neurotoxic? Schizophr Bull. 2006;32:609-613.
15. Emsley R, Medori R, Koen L, et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008;28:210-213.
16. First MB, Spitzer RLGM, Williams LBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P). 2nd ed. New York, NY: New York State Psychiatric Institute, Biometrics Research; 1994.
17. Emsley R, Oosthuizen PP, Koen L, et al. Symptom recurrence following intermittent treatment in first episode schizophrenia successfully treated for two years: a 3 yr open-label study. J Clin Psychiatry. 2012;73(4):e541-e547.
18. Kay SR, Fizbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull. 1987;13:261-267.
19. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
20. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538-546.
21. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
22. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
23. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
24. Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980;137:16-21.